J&J Seeks Europe Okay for Spravato in Imminent Suicide Risk

Date : 01/15/2020 @ 1:25PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 133.83  -5.29 (-3.80%) @ 4:33PM

J&J Seeks Europe Okay for Spravato in Imminent Suicide Risk

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Wednesday said it filed with the European Medicines Agency for expanded use of its Spravato nasal spray in adults at imminent risk for suicide.

The drug maker said it is seeking European approval for Spravato as an acute short-term treatment, co-administered with oral antidepressant therapy, for the rapid reduction of depressive symptoms in adults with a moderate-to-severe depressive episode of major depressive disorder who have current suicidal ideation with intent.

The European Commission last month approved Spravato for adults with treatment-resistant major depressive disorder.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

January 15, 2020 08:10 ET (13:10 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.